Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of s...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology Jg. 13; H. 3; S. 300 - 308 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
01.03.2012
Elsevier Limited |
| Schlagworte: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC.
TITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1:1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov, number NCT00556322.
Between April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27·9 months (IQR 11·0–36·0) in the erlotinib group and 24·8 months (12·1–41·6) in the chemotherapy group. Median overall survival was 5·3 months (95% CI 4·0–6·0) with erlotinib and 5·5 months (4·4–7·1) with chemotherapy (hazard ratio [HR] 0·96, 95% CI 0·78–1·19; log-rank p=0·73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy.
No significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles.
F Hoffmann-La Roche. |
|---|---|
| AbstractList | Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC.BACKGROUNDErlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC.TITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1:1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov, number NCT00556322.METHODSTITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1:1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov, number NCT00556322.Between April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27·9 months (IQR 11·0-36·0) in the erlotinib group and 24·8 months (12·1-41·6) in the chemotherapy group. Median overall survival was 5·3 months (95% CI 4·0-6·0) with erlotinib and 5·5 months (4·4-7·1) with chemotherapy (hazard ratio [HR] 0·96, 95% CI 0·78-1·19; log-rank p=0·73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy.FINDINGSBetween April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27·9 months (IQR 11·0-36·0) in the erlotinib group and 24·8 months (12·1-41·6) in the chemotherapy group. Median overall survival was 5·3 months (95% CI 4·0-6·0) with erlotinib and 5·5 months (4·4-7·1) with chemotherapy (hazard ratio [HR] 0·96, 95% CI 0·78-1·19; log-rank p=0·73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy.No significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles.INTERPRETATIONNo significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles.F Hoffmann-La Roche.FUNDINGF Hoffmann-La Roche. Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. TITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1:1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov, number NCT00556322. Between April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27·9 months (IQR 11·0-36·0) in the erlotinib group and 24·8 months (12·1-41·6) in the chemotherapy group. Median overall survival was 5·3 months (95% CI 4·0-6·0) with erlotinib and 5·5 months (4·4-7·1) with chemotherapy (hazard ratio [HR] 0·96, 95% CI 0·78-1·19; log-rank p=0·73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy. No significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles. F Hoffmann-La Roche. Summary Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. Methods TITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1:1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov , number NCT00556322. Findings Between April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27·9 months (IQR 11·0–36·0) in the erlotinib group and 24·8 months (12·1–41·6) in the chemotherapy group. Median overall survival was 5·3 months (95% CI 4·0–6·0) with erlotinib and 5·5 months (4·4–7·1) with chemotherapy (hazard ratio [HR] 0·96, 95% CI 0·78–1·19; log-rank p=0·73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy. Interpretation No significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles. Funding F Hoffmann-La Roche. Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. Methods: TITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1: 1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov, number NCT00556322. Findings: Between April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27.9 months (IQR 11.0-36.0) in the erlotinib group and 24.8 months (12.1-41.6) in the chemotherapy group. Median overall survival was 5.3 months (95% CI 4.0-6.0) with erlotinib and 5.5 months (4.4-7.1) with chemotherapy (hazard ratio [HR] 0.96, 95% CI 0.78-1.19; log-rank p=0.73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy. Interpretation: No significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles. Funding: F Hoffmann-La Roche. Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials are available. We undertook the Tarceva In Treatment of Advanced NSCLC (TITAN) study to assess the efficacy and tolerability of second-line erlotinib versus chemotherapy in patients with refractory NSCLC. TITAN was an international, randomised multicentre, open-label, phase 3 study that was done at 77 sites in 24 countries. Chemotherapy-naive patients with locally advanced, recurrent, or metastatic NSCLC received up to four cycles of first-line platinum doublet chemotherapy, after which patients with disease progression during or immediately after chemotherapy were offered enrolment into TITAN. Enrolled patients were randomly assigned (1:1) by a minimisation method to ensure balanced stratification, to receive erlotinib 150 mg/day or chemotherapy (standard docetaxel or pemetrexed regimens, at the treating investigators' discretion), until unacceptable toxicity, disease progression, or death. Patients were stratified by disease stage, Eastern Cooperative Oncology Group performance status, smoking history, and region of residence. The primary endpoint was overall survival in the intention-to-treat population. TITAN was halted prematurely because of slow recruitment. This study is registered with ClinicalTrials.gov, number NCT00556322. Between April 10, 2006, and Feb 24, 2010, 2590 chemotherapy-naive patients were treated with first-line platinum doublet chemotherapy, of whom 424 had disease progression and were enrolled into TITAN. 203 patients were randomly assigned to receive erlotinib and 221 were assigned to receive chemotherapy. Median follow-up was 27·9 months (IQR 11·0-36·0) in the erlotinib group and 24·8 months (12·1-41·6) in the chemotherapy group. Median overall survival was 5·3 months (95% CI 4·0-6·0) with erlotinib and 5·5 months (4·4-7·1) with chemotherapy (hazard ratio [HR] 0·96, 95% CI 0·78-1·19; log-rank p=0·73). The adverse-event profile of each group was in line with previous studies. Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy. No significant differences in efficacy were noted between patients treated with erlotinib and those treated with docetaxel or pemetrexed. Since the toxicity profiles of erlotinib and chemotherapy differ, second-line treatment decisions should take into account patient preference and specific toxicity risk profiles. F Hoffmann-La Roche. |
| Author | Johannsdottir, Hrefna Kristin Cicenas, Saulius Stelmakh, Lilia Ciuleanu, Tudor Klughammer, Barbara Miliauskas, Skaidrius Grigorescu, Alexandru Calin Hillenbach, Carina Gonzalez, Emilio Esteban |
| Author_xml | – sequence: 1 givenname: Tudor surname: Ciuleanu fullname: Ciuleanu, Tudor email: tudor@iocn.ro organization: Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania – sequence: 2 givenname: Lilia surname: Stelmakh fullname: Stelmakh, Lilia organization: Pavlov State Medical University, St Petersburg, Russia – sequence: 3 givenname: Saulius surname: Cicenas fullname: Cicenas, Saulius organization: Vilnius University, Faculty of Medicine, Institute of Oncology, Vilnius, Lithuania – sequence: 4 givenname: Skaidrius surname: Miliauskas fullname: Miliauskas, Skaidrius organization: Hospital of Lithuanian University of Health Sciences, Kaunas, Lithuania – sequence: 5 givenname: Alexandru Calin surname: Grigorescu fullname: Grigorescu, Alexandru Calin organization: Institute of Oncology Alexandru Trestioreanu, Bucharest, Romania – sequence: 6 givenname: Carina surname: Hillenbach fullname: Hillenbach, Carina organization: F Hoffmann-La Roche, Basel, Switzerland – sequence: 7 givenname: Hrefna Kristin surname: Johannsdottir fullname: Johannsdottir, Hrefna Kristin organization: F Hoffmann-La Roche, Basel, Switzerland – sequence: 8 givenname: Barbara surname: Klughammer fullname: Klughammer, Barbara organization: F Hoffmann-La Roche, Basel, Switzerland – sequence: 9 givenname: Emilio Esteban surname: Gonzalez fullname: Gonzalez, Emilio Esteban organization: Hospital General de Asturias, Oviedo, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22277837$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks1u1DAUhSNURH_gEUAWG6bSBOw4iRMQoKoqUKmCBbO3HOem4-LYqe0MynvyQDgzLYuRoKxsJ-d-Pr73HCcHxhpIkucEvyaYlG--k5zhNMN5sSDklGFaFSl-lBzFz3la5FV1sN3vJIfJsfc3GBNGcPEkOcyyjLGKsqPk10XXKSnkhIRpkRcdhAnZDoHTNiijGrQB50eP5Bp6G9bgxDAhZZAHaU2bamUABQci9GDCXDmIoOLWo58qrJFoN8JIaJco-k99L7ROJWiN9GiukZz_uZ1ysNahwdlrY73yaLG6XJ19PX2LBHLRmu2Vhxb1ow5KRryDJbIDmFSLBvQSDWvhAVHkw9hOT5PHndAent2tJ8nq08Xq_Et69e3z5fnZVSoLSkOaFwIDrTHOBc3roqOiqTpZtqxsRNVRXNd1FQ-ipJiJEtqMUNaW0JVQNA2m9CR5tcNG17cj-MCjyflxwoAdPa-zkhQly1lULv6pJBhXFa3KPI_Sl3vSGzs6E58ReaygWVnhKHpxJxqbHlo-ONULN_H7uUbBu51AOuu9g45LFeJgbOycUDpeyOcU8W2K-BwRTgjfpojP-GKv-v6Ch-o-7uogNn2jwHEvYxbi-JUDGXhr1YOED3sEGRMWA6p_wAT-TysI9xnHO8jMIGRLmAHv_w74DwO_AeiMCNk |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1038_s41467_017_01430_6 crossref_primary_10_1016_j_critrevonc_2015_05_007 crossref_primary_10_1200_JCO_2013_50_8705 crossref_primary_10_1016_j_cllc_2017_06_002 crossref_primary_10_3892_or_2013_2553 crossref_primary_10_1038_s41368_025_00382_8 crossref_primary_10_3390_pharmaceutics13122120 crossref_primary_10_1007_s11596_016_1672_x crossref_primary_10_3389_fphar_2025_1519849 crossref_primary_10_3389_fonc_2025_1489327 crossref_primary_10_4103_ijc_IJC_136_17 crossref_primary_10_1097_CAD_0b013e3283585149 crossref_primary_10_1111_jcpt_12332 crossref_primary_10_1007_s12254_012_0050_z crossref_primary_10_1093_annonc_mdw569 crossref_primary_10_1093_annonc_mdw326 crossref_primary_10_1007_s11523_017_0517_2 crossref_primary_10_1097_COC_0b013e318287bb23 crossref_primary_10_3892_ol_2019_10942 crossref_primary_10_1016_j_lungcan_2015_03_006 crossref_primary_10_1586_17512433_2014_945430 crossref_primary_10_1016_j_lungcan_2016_05_016 crossref_primary_10_1007_s40801_023_00383_1 crossref_primary_10_1016_j_bbcan_2015_08_002 crossref_primary_10_1016_j_cllc_2019_06_017 crossref_primary_10_1136_jitc_2022_006055 crossref_primary_10_1111_ajco_12199 crossref_primary_10_1200_JCO_2014_58_1603 crossref_primary_10_1016_j_jtho_2017_11_111 crossref_primary_10_1200_JCO_2013_52_4694 crossref_primary_10_1007_s10549_018_05102_x crossref_primary_10_1159_000442344 crossref_primary_10_1080_14656566_2018_1540591 crossref_primary_10_1007_s00520_017_3629_4 crossref_primary_10_2217_lmt_12_29 crossref_primary_10_3402_ecrj_v3_32633 crossref_primary_10_1016_j_cllc_2015_02_006 crossref_primary_10_2217_lmt_12_4 crossref_primary_10_1007_s11060_022_04110_8 crossref_primary_10_1016_j_cllc_2017_03_005 crossref_primary_10_1007_s13277_015_3660_3 crossref_primary_10_1159_000519847 crossref_primary_10_1185_03007995_2014_978448 crossref_primary_10_1016_j_ctrv_2013_05_005 crossref_primary_10_1016_j_addr_2018_08_012 crossref_primary_10_1159_000510103 crossref_primary_10_1016_j_lungcan_2013_12_007 crossref_primary_10_1093_annonc_mdu123 crossref_primary_10_3310_hta19470 crossref_primary_10_1002_cncr_30718 crossref_primary_10_1111_1759_7714_13090 crossref_primary_10_1002_cam4_1121 crossref_primary_10_1002_cncr_30717 crossref_primary_10_1371_journal_pone_0196350 crossref_primary_10_1371_journal_pone_0085245 crossref_primary_10_1186_s12964_022_00840_4 crossref_primary_10_1186_s12885_021_08920_3 crossref_primary_10_2217_fon_2016_0180 crossref_primary_10_1016_j_lungcan_2018_06_032 crossref_primary_10_1016_j_critrevonc_2013_08_003 crossref_primary_10_3892_ol_2014_2548 crossref_primary_10_1016_j_jaad_2017_01_060 crossref_primary_10_1016_j_hoc_2016_08_002 crossref_primary_10_1016_j_critrevonc_2021_103305 crossref_primary_10_1177_1753465815588053 crossref_primary_10_1097_COC_0000000000000179 crossref_primary_10_1049_nbt2_12028 crossref_primary_10_1093_annonc_mdu199 crossref_primary_10_1159_000444186 crossref_primary_10_1002_cncr_28591 crossref_primary_10_1586_erp_12_42 crossref_primary_10_1016_j_lungcan_2016_01_024 crossref_primary_10_1517_14656566_2014_909412 crossref_primary_10_3390_cancers14010092 crossref_primary_10_1016_j_jconrel_2017_05_023 crossref_primary_10_1080_17476348_2016_1240620 crossref_primary_10_1371_journal_pone_0095897 crossref_primary_10_1097_MD_0000000000002495 crossref_primary_10_3389_fonc_2020_578756 crossref_primary_10_1002_cjp2_15 crossref_primary_10_1016_j_lungcan_2021_09_007 crossref_primary_10_1186_s12913_022_07857_y crossref_primary_10_1517_17460441_2013_813015 crossref_primary_10_3390_jcm7080192 crossref_primary_10_1371_journal_pone_0055637 crossref_primary_10_1016_j_lungcan_2014_03_026 crossref_primary_10_1634_theoncologist_2018_0089 crossref_primary_10_1007_s10637_017_0515_3 crossref_primary_10_1016_j_critrevonc_2020_103035 crossref_primary_10_1097_MD_0000000000001719 crossref_primary_10_3389_fgene_2022_949241 crossref_primary_10_1016_j_tips_2016_05_010 crossref_primary_10_1517_14656566_2014_957179 crossref_primary_10_1016_S1470_2045_12_70123_7 crossref_primary_10_1371_journal_pone_0070346 crossref_primary_10_2217_fon_2018_0948 crossref_primary_10_1007_s13277_015_4093_8 crossref_primary_10_1007_s11523_024_01073_w crossref_primary_10_1159_000351607 crossref_primary_10_1016_S1470_2045_12_70001_3 crossref_primary_10_1186_1752_1947_8_102 crossref_primary_10_1586_14737140_2015_1071669 crossref_primary_10_1016_j_tranon_2014_02_017 crossref_primary_10_2217_fon_13_6 crossref_primary_10_3892_mco_2017_1408 crossref_primary_10_1177_11795549231215968 crossref_primary_10_5582_bst_2018_01246 crossref_primary_10_1016_j_cellsig_2021_110092 crossref_primary_10_2217_fon_14_290 crossref_primary_10_1007_s12094_015_1424_6 crossref_primary_10_1016_j_lungcan_2013_11_003 crossref_primary_10_3390_cells10051206 crossref_primary_10_1371_journal_pone_0234818 crossref_primary_10_4161_cc_26417 crossref_primary_10_1371_journal_pone_0128970 crossref_primary_10_1093_annonc_mdv390 crossref_primary_10_1371_journal_pone_0200015 crossref_primary_10_1634_theoncologist_2015_0209 crossref_primary_10_5301_JBM_5000039 crossref_primary_10_1586_14737140_2014_983083 crossref_primary_10_1586_14737140_2015_1031218 crossref_primary_10_1016_S1470_2045_14_70162_7 crossref_primary_10_1016_j_rmr_2013_05_011 crossref_primary_10_1200_JCO_2012_46_2648 crossref_primary_10_3390_jpm4030386 crossref_primary_10_1016_j_lungcan_2013_11_016 crossref_primary_10_1517_14728222_2013_729043 crossref_primary_10_1002_ijc_28925 crossref_primary_10_1371_journal_pone_0081975 crossref_primary_10_3892_mmr_2017_7144 crossref_primary_10_1016_j_ctrv_2012_09_001 crossref_primary_10_1016_j_cllc_2015_08_003 crossref_primary_10_1002_14651858_CD014872_pub2 crossref_primary_10_1177_2515690X211010733 crossref_primary_10_1007_s40265_016_0628_6 crossref_primary_10_1016_j_lungcan_2014_07_006 crossref_primary_10_1124_jpet_114_215418 crossref_primary_10_1016_j_biocel_2017_10_008 crossref_primary_10_1016_j_rmcr_2013_06_003 crossref_primary_10_1016_S1470_2045_12_70113_4 crossref_primary_10_1093_jnci_djt072 crossref_primary_10_3389_fphar_2022_862640 crossref_primary_10_1186_s40880_015_0036_4 crossref_primary_10_1634_theoncologist_2014_0154 crossref_primary_10_1007_s13277_015_3893_1 crossref_primary_10_1097_JTO_0b013e31828cb505 crossref_primary_10_3892_ol_2023_13788 crossref_primary_10_1016_j_jtho_2015_12_107 crossref_primary_10_1097_MD_0000000000005601 crossref_primary_10_1111_ijd_12205 crossref_primary_10_1371_journal_pone_0136640 crossref_primary_10_1111_cup_14145 crossref_primary_10_3389_fmed_2016_00065 crossref_primary_10_1517_14656566_2015_1040391 crossref_primary_10_1371_journal_pone_0102777 crossref_primary_10_2217_fon_15_358 crossref_primary_10_3389_fonc_2019_00589 crossref_primary_10_1016_j_lungcan_2014_07_011 crossref_primary_10_1634_theoncologist_2013_0096 crossref_primary_10_2217_fon_15_356 crossref_primary_10_2217_lmt_2016_0010 crossref_primary_10_1016_j_advms_2014_08_008 crossref_primary_10_1097_MD_0000000000016048 crossref_primary_10_1016_j_ijpharm_2015_12_073 crossref_primary_10_1200_JCO_2012_43_4522 crossref_primary_10_18632_oncotarget_15475 crossref_primary_10_1586_17476348_2014_861744 crossref_primary_10_1016_j_jaad_2014_12_010 crossref_primary_10_1016_S1470_2045_16_30561_7 crossref_primary_10_1016_j_cllc_2016_10_003 crossref_primary_10_2217_lmt_13_74 crossref_primary_10_2217_lmt_14_45 crossref_primary_10_2217_cer_2022_0016 crossref_primary_10_1002_cncr_28132 crossref_primary_10_1016_j_lungcan_2016_07_027 crossref_primary_10_1586_14737140_2015_1014035 crossref_primary_10_1177_1758834013510589 crossref_primary_10_1016_j_cllc_2014_11_007 crossref_primary_10_1158_1078_0432_CCR_18_0651 crossref_primary_10_1200_JCO_2014_57_5449 crossref_primary_10_1016_j_lfs_2021_120293 crossref_primary_10_1093_annonc_mds226 crossref_primary_10_18632_oncotarget_20281 crossref_primary_10_1016_j_clinthera_2013_08_007 crossref_primary_10_1007_s11523_015_0376_7 crossref_primary_10_1016_j_bbrc_2022_10_053 crossref_primary_10_1016_j_ctarc_2020_100200 crossref_primary_10_1183_16000617_00002115 crossref_primary_10_1177_1758834013492001 crossref_primary_10_1016_S1470_2045_13_70310_3 crossref_primary_10_1007_s11864_025_01336_2 crossref_primary_10_1002_cam4_180 crossref_primary_10_3389_fmed_2017_00036 crossref_primary_10_3389_fonc_2021_792385 crossref_primary_10_1080_14656566_2017_1285284 crossref_primary_10_1186_s12885_018_4208_x crossref_primary_10_1517_14656566_2016_1109635 crossref_primary_10_1002_adbi_201800223 crossref_primary_10_3389_fonc_2020_01531 crossref_primary_10_1200_JCO_2015_62_1342 crossref_primary_10_1097_MD_0000000000034483 crossref_primary_10_1007_s11864_023_01159_z crossref_primary_10_1186_s40247_015_0013_z crossref_primary_10_1007_s10555_015_9560_6 crossref_primary_10_1016_j_clinthera_2016_12_008 crossref_primary_10_1093_annonc_mdu463 crossref_primary_10_1007_s11523_017_0515_4 crossref_primary_10_3892_ol_2012_1048 crossref_primary_10_3390_cancers10070236 crossref_primary_10_1371_journal_pone_0142500 crossref_primary_10_1371_journal_pone_0215135 crossref_primary_10_1007_s00280_015_2740_9 crossref_primary_10_1183_13993003_00514_2017 crossref_primary_10_1016_j_cllc_2012_05_009 crossref_primary_10_14694_EdBook_AM_2012_32_437 crossref_primary_10_1016_S1470_2045_13_70586_2 crossref_primary_10_1016_j_jtho_2016_12_017 crossref_primary_10_1093_annonc_mdy275 crossref_primary_10_1186_1465_9921_14_139 crossref_primary_10_1179_1973947814Y_0000000189 crossref_primary_10_1200_JCO_2013_54_4270 crossref_primary_10_1111_dth_12027 crossref_primary_10_3389_fmed_2017_00009 crossref_primary_10_1016_j_lungcan_2017_11_015 crossref_primary_10_1093_annonc_mdu575 crossref_primary_10_1007_s00432_013_1483_4 crossref_primary_10_1016_j_lungcan_2014_05_024 crossref_primary_10_51847_zw5UfuNJWX crossref_primary_10_1093_jjco_hyz088 crossref_primary_10_1586_era_12_110 crossref_primary_10_2217_lmt_13_39 crossref_primary_10_2217_fon_2016_0493 crossref_primary_10_1016_j_critrevonc_2013_11_008 crossref_primary_10_1177_1534735420924832 crossref_primary_10_51847_nflq8014mf8933 crossref_primary_10_2147_IJGM_S316344 crossref_primary_10_3389_fmed_2017_00004 crossref_primary_10_1586_era_12_119 crossref_primary_10_1016_j_lungcan_2015_06_017 crossref_primary_10_1016_j_lungcan_2012_12_025 crossref_primary_10_1016_j_jaad_2013_06_038 crossref_primary_10_1371_journal_pone_0087629 crossref_primary_10_1111_jcmm_12278 crossref_primary_10_1007_s11864_016_0437_x crossref_primary_10_2217_lmt_13_43 crossref_primary_10_1016_j_prp_2016_06_005 crossref_primary_10_1200_JCO_2013_50_2617 crossref_primary_10_5306_wjco_v4_i2_29 |
| Cites_doi | 10.1200/JCO.2004.08.163 10.1158/1078-0432.CCR-05-1492 10.1200/JCO.2000.18.12.2354 10.1172/JCI37127 10.1200/JCO.2008.19.1650 10.1016/S0140-6736(08)61758-4 10.1200/JCO.2005.04.4420 10.1200/JCO.2010.31.8162 10.1200/JCO.2009.24.3030 10.1200/JCO.2008.17.5844 10.1016/S1470-2045(10)70112-1 10.1056/NEJMoa050753 10.1093/jnci/dji055 10.1200/JCO.2000.18.10.2095 10.1200/JCO.2007.14.8924 10.2307/2529712 |
| ContentType | Journal Article |
| Copyright | 2012 Elsevier Ltd Elsevier Ltd Copyright © 2012 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Mar 2012 |
| Copyright_xml | – notice: 2012 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2012 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Mar 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(11)70385-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Oncogenes and Growth Factors Abstracts Oncogenes and Growth Factors Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 308 |
| ExternalDocumentID | 2606994931 22277837 10_1016_S1470_2045_11_70385_0 S1470204511703850 1_s2_0_S1470204511703850 |
| Genre | Clinical Trial, Phase III Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GrantInformation | F Hoffmann-La Roche. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c533t-45a0e39004a3495f3ab8fc6d76ba8f309998d76a6307a6ed2137d6ef6e5bb033 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 327 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000300880600038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Thu Oct 02 11:39:51 EDT 2025 Sun Nov 09 14:42:12 EST 2025 Tue Oct 07 05:27:06 EDT 2025 Mon Jul 21 05:59:33 EDT 2025 Sat Nov 29 06:59:35 EST 2025 Tue Nov 18 22:14:46 EST 2025 Fri Feb 23 02:29:55 EST 2024 Sun Feb 23 10:18:54 EST 2025 Tue Oct 14 19:34:41 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2012 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c533t-45a0e39004a3495f3ab8fc6d76ba8f309998d76a6307a6ed2137d6ef6e5bb033 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-General Information-1 content type line 14 ObjectType-Feature-3 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Undefined-3 |
| PMID | 22277837 |
| PQID | 927532680 |
| PQPubID | 46089 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_926156747 proquest_miscellaneous_1008838644 proquest_journals_927532680 pubmed_primary_22277837 crossref_citationtrail_10_1016_S1470_2045_11_70385_0 crossref_primary_10_1016_S1470_2045_11_70385_0 elsevier_sciencedirect_doi_10_1016_S1470_2045_11_70385_0 elsevier_clinicalkeyesjournals_1_s2_0_S1470204511703850 elsevier_clinicalkey_doi_10_1016_S1470_2045_11_70385_0 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-03-01 |
| PublicationDateYYYYMMDD | 2012-03-01 |
| PublicationDate_xml | – month: 03 year: 2012 text: 2012-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2012 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Fossella, DeVore, Kerr (bib5) 2000; 18 Cappuzzo, Ciuleanu, Stelmakh (bib9) 2010; 11 Brugger, Triller, Blasinska-Morawiec (bib10) 2011; 29 Vamvakas, Agelaki, Kentepozidis (bib18) 2010; 28 Shepherd, Tsao (bib14) 2006; 24 Douillard, Shepherd, Hirsh (bib11) 2010; 28 Yauch, Januario, Eberhard (bib15) 2005; 11 Kim, Hirsh, Mok (bib6) 2008; 372 Sos, Michel, Zander (bib16) 2009; 119 Shepherd, Dancey, Ramlau (bib4) 2000; 18 Favaretto, Pasello, Magro (bib1) 2009; 8 Shepherd, Rodrigues Pereira, Ciuleanu (bib8) 2005; 353 Di Maio, Chiodini, Georgoulias (bib2) 2009; 27 Smit, Burgers, Biesma (bib3) 2009; 27 Shigematsu, Lin, Takahashi (bib13) 2005; 97 Hanna, Shepherd, Fossella (bib7) 2004; 22 Pocock, Simon (bib12) 1975; 31 Zhu, da Cunha Santos, Ding (bib17) 2008; 26 Di Maio (10.1016/S1470-2045(11)70385-0_bib2) 2009; 27 Cappuzzo (10.1016/S1470-2045(11)70385-0_bib9) 2010; 11 Shepherd (10.1016/S1470-2045(11)70385-0_bib4) 2000; 18 Sos (10.1016/S1470-2045(11)70385-0_bib16) 2009; 119 Douillard (10.1016/S1470-2045(11)70385-0_bib11) 2010; 28 Shigematsu (10.1016/S1470-2045(11)70385-0_bib13) 2005; 97 Shepherd (10.1016/S1470-2045(11)70385-0_bib14) 2006; 24 Vamvakas (10.1016/S1470-2045(11)70385-0_bib18) 2010; 28 Favaretto (10.1016/S1470-2045(11)70385-0_bib1) 2009; 8 Yauch (10.1016/S1470-2045(11)70385-0_bib15) 2005; 11 Shepherd (10.1016/S1470-2045(11)70385-0_bib8) 2005; 353 Brugger (10.1016/S1470-2045(11)70385-0_bib10) 2011; 29 Smit (10.1016/S1470-2045(11)70385-0_bib3) 2009; 27 Hanna (10.1016/S1470-2045(11)70385-0_bib7) 2004; 22 Pocock (10.1016/S1470-2045(11)70385-0_bib12) 1975; 31 Zhu (10.1016/S1470-2045(11)70385-0_bib17) 2008; 26 Fossella (10.1016/S1470-2045(11)70385-0_bib5) 2000; 18 Kim (10.1016/S1470-2045(11)70385-0_bib6) 2008; 372 22277836 - Lancet Oncol. 2012 Mar;13(3):225-7 22469123 - Lancet Oncol. 2012 Apr;13(4):e141-2; author reply e142 |
| References_xml | – volume: 353 start-page: 123 year: 2005 end-page: 132 ident: bib8 article-title: Erlotinib in previously treated non-small-cell lung cancer publication-title: N Engl J Med – volume: 11 start-page: 521 year: 2010 end-page: 529 ident: bib9 article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study publication-title: Lancet Oncol – volume: 22 start-page: 1589 year: 2004 end-page: 1597 ident: bib7 article-title: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy publication-title: J Clin Oncol – volume: 28 start-page: 744 year: 2010 end-page: 752 ident: bib11 article-title: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial publication-title: J Clin Oncol – volume: 28 year: 2010 ident: bib18 article-title: Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial publication-title: Proc Am Soc Clin Oncol – volume: 18 start-page: 2095 year: 2000 end-page: 2103 ident: bib4 article-title: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy publication-title: J Clin Oncol – volume: 27 start-page: 2038 year: 2009 end-page: 2045 ident: bib3 article-title: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer publication-title: J Clin Oncol – volume: 31 start-page: 103 year: 1975 end-page: 115 ident: bib12 article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial publication-title: Biometrics – volume: 11 start-page: 8686 year: 2005 end-page: 8698 ident: bib15 article-title: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients publication-title: Clin Cancer Res – volume: 26 start-page: 4268 year: 2008 end-page: 4275 ident: bib17 article-title: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 publication-title: J Clin Oncol – volume: 8 start-page: 204 year: 2009 end-page: 209 ident: bib1 article-title: Second and third line treatment in advanced non-small cell lung cancer publication-title: Discov Med – volume: 372 start-page: 1809 year: 2008 end-page: 1818 ident: bib6 article-title: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial publication-title: Lancet – volume: 97 start-page: 339 year: 2005 end-page: 346 ident: bib13 article-title: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers publication-title: J Natl Cancer Inst – volume: 27 start-page: 1836 year: 2009 end-page: 1843 ident: bib2 article-title: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer publication-title: J Clin Oncol – volume: 18 start-page: 2354 year: 2000 end-page: 2362 ident: bib5 article-title: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group publication-title: J Clin Oncol – volume: 119 start-page: 1727 year: 2009 end-page: 1740 ident: bib16 article-title: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions publication-title: J Clin Invest – volume: 24 start-page: 1219 year: 2006 end-page: 1220 ident: bib14 article-title: Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy publication-title: J Clin Oncol – volume: 29 start-page: 4113 year: 2011 end-page: 4120 ident: bib10 article-title: Prospective molecular marker analyses of publication-title: J Clin Oncol – volume: 22 start-page: 1589 year: 2004 ident: 10.1016/S1470-2045(11)70385-0_bib7 article-title: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2004.08.163 – volume: 11 start-page: 8686 year: 2005 ident: 10.1016/S1470-2045(11)70385-0_bib15 article-title: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1492 – volume: 18 start-page: 2354 year: 2000 ident: 10.1016/S1470-2045(11)70385-0_bib5 article-title: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.12.2354 – volume: 119 start-page: 1727 year: 2009 ident: 10.1016/S1470-2045(11)70385-0_bib16 article-title: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions publication-title: J Clin Invest doi: 10.1172/JCI37127 – volume: 28 issue: suppl year: 2010 ident: 10.1016/S1470-2045(11)70385-0_bib18 article-title: Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial publication-title: Proc Am Soc Clin Oncol – volume: 27 start-page: 2038 year: 2009 ident: 10.1016/S1470-2045(11)70385-0_bib3 article-title: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.19.1650 – volume: 372 start-page: 1809 year: 2008 ident: 10.1016/S1470-2045(11)70385-0_bib6 article-title: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial publication-title: Lancet doi: 10.1016/S0140-6736(08)61758-4 – volume: 8 start-page: 204 year: 2009 ident: 10.1016/S1470-2045(11)70385-0_bib1 article-title: Second and third line treatment in advanced non-small cell lung cancer publication-title: Discov Med – volume: 24 start-page: 1219 year: 2006 ident: 10.1016/S1470-2045(11)70385-0_bib14 article-title: Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.4420 – volume: 29 start-page: 4113 year: 2011 ident: 10.1016/S1470-2045(11)70385-0_bib10 article-title: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2010.31.8162 – volume: 28 start-page: 744 year: 2010 ident: 10.1016/S1470-2045(11)70385-0_bib11 article-title: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.3030 – volume: 27 start-page: 1836 year: 2009 ident: 10.1016/S1470-2045(11)70385-0_bib2 article-title: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.5844 – volume: 11 start-page: 521 year: 2010 ident: 10.1016/S1470-2045(11)70385-0_bib9 article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70112-1 – volume: 353 start-page: 123 year: 2005 ident: 10.1016/S1470-2045(11)70385-0_bib8 article-title: Erlotinib in previously treated non-small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa050753 – volume: 97 start-page: 339 year: 2005 ident: 10.1016/S1470-2045(11)70385-0_bib13 article-title: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji055 – volume: 18 start-page: 2095 year: 2000 ident: 10.1016/S1470-2045(11)70385-0_bib4 article-title: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.10.2095 – volume: 26 start-page: 4268 year: 2008 ident: 10.1016/S1470-2045(11)70385-0_bib17 article-title: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.14.8924 – volume: 31 start-page: 103 year: 1975 ident: 10.1016/S1470-2045(11)70385-0_bib12 article-title: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial publication-title: Biometrics doi: 10.2307/2529712 – reference: 22469123 - Lancet Oncol. 2012 Apr;13(4):e141-2; author reply e142 – reference: 22277836 - Lancet Oncol. 2012 Mar;13(3):225-7 |
| SSID | ssj0017105 |
| Score | 2.5363295 |
| Snippet | Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head data from large... Summary Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment of non-small-cell lung cancer (NSCLC), but no head-to-head... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 300 |
| SubjectTerms | Adult Aged Aged, 80 and over Alopecia Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - secondary Chemotherapy Chi-Square Distribution Clinical trials Data processing Diarrhea Dihydrofolate reductase Drugs Early Termination of Clinical Trials Erlotinib Hydrochloride Europe Exanthema Female Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Kaplan-Meier Estimate Kinases Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - pathology Male Medical prognosis Metastases Metastasis Middle Aged Mutation Oncology Patients Pemetrexed Platinum Prognosis Prospective Studies Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Recruitment Salvage Therapy Smoking Survival Taxoids - administration & dosage Time Factors Toxicity Treatment Outcome |
| Title | Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204511703850 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204511703850 https://dx.doi.org/10.1016/S1470-2045(11)70385-0 https://www.ncbi.nlm.nih.gov/pubmed/22277837 https://www.proquest.com/docview/927532680 https://www.proquest.com/docview/1008838644 https://www.proquest.com/docview/926156747 |
| Volume | 13 |
| WOSCitedRecordID | wos000300880600038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: AUTh Library subscriptions: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF7RFiEuvB-hUA0Sh1bKUttr7665oFKlggNRVSKUm7W21yKSa4dsgpT_yQ9ixi8uhCJxseTHaJ3s7Mw3nm9nGHsjo8B4oYp4mBcpD-M84KnIPO5LyjnJ0HrGNM0m1HSq5_P4suPmuI5W2dvExlDndUbfyE_jAIF1ILX3fvmdU9MoSq52HTT22IEfeCGtS30-MDx81TIY_VB5nKqu_97Ac_pluHjs-yeK0mPc2-WadkHPxgVd3P_Pl3_A7nXYE85aZXnIbtnqEbvzucuuP2Y_J1RPwmRbMFUOzhR2vYW6ALsq6_WiWqRAHI6NA5zo627n1hYWFTiKqnNOiBUG5jpJdlVbHdDnXuj5BmOo6oq7a1OWnBIHUKLFgYzurdonl3W9AqKOVbVbODiefZqdTU_egQF0rXmNumlzaLiQDbnUjoG6gHHUaFuOYfkNXTMIaErnPmGzi8ns_CPvuj7wDKHnmoeR8ayIcfEagdFbIUyqi0zmSqZGF4IQrcYTI9E6GWnzwBcql7aQNkpTT4inbB9_hH3OINM2yPzANzqNwrTQcRgV1viZCLWMcqVHLOznO8m6iujUmKNMBuobqUlCaoKRUtKoSeKN2NtBbNmWBLlJQPbKlPT7XdFCJ-i0bhJUfxK0rrMzLvETFyReK03C1EcIRVFSD5IdlGoh0r8MetjrcDKMMyjwiL0e7uJkk5KYytYbR8WvtRYa8fWIwY5nYozXI4kR7Ig9a1fS8A_SnmylhXrx1-EP2V1ErEFLAnzJ9terjX3Fbmc_1gu3OmJ76uorHeeqOeqjxiAcsYMPk-nl1S_pm2I6 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqgoAL78dSHoMEUiutaeIkjhcJoaq0atV2hcQeerOcxBErpcmy3gXtf-Ln8IOYyYsLS7n0wDGPkRVnZvyN_c0MY69lJIwXxhEPszzh4SgTPAlSj_uSzpxkaD1j6mYT8Xiszs9HnzbYjy4XhmiVnU-sHXVWpbRHvjsSCKyFVN6H2VdOTaPocLXroNFoxYldfceIzb0__oi_940QhweT_SPeNhXgKSKbBQ8j41kM9L3QBBgc5IFJVJ7KLJaJUXlAgEnhhZGo_EbaTPhBnEmbSxsliUfbn-jwr1EdOwr11H5PKPHjhjDph7HHqcj773yh3c_9zW3f34npNI5761bCdUi3XvEO7_xfc3WX3W6RNew1pnCPbdjyPrtx1nIHHrCfB1Qtw6QrMGUGzuR2sYIqBzsvqsW0nCZADJWlA1TjizYvbQXTEhztGWSc8Dj0vHySbGvSOqDNbOjYFEMoq5K7C1MUnI5FoEB_Cik9mzdvzqpqDkSMKys3dbA9OZ7sjXfegQEEDlmFlmczqJmeNXXWDoF6nHG0V1sMYfYFgQcEUBcGfsgmVzGlj9gmfoR9wiBVVqS-8I1KojDJ1SiMcmv8NAiVjLJYDVjYqZdO23rv1Hak0D2xj7RSk1ZiHKhrrdTegL3txWZNwZPLBGSnu7rL5sX1R-OSfJlg_CdB61ov6rSvndBeI03C1CUJRVFS9ZItUGwA4L8MutWZjO7H6e1lwF71T_Fnk5KY0lZLR6W9lQoURg8DBmveGQkMDyTG5wP2uDHcfgYp4zxWQfz0r8O_ZDePJmen-vR4fLLFbiE2Fw3d8RnbXMyX9jm7nn5bTN38Re15gOkrtt5fvhq5Yg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELaqgiouvB-hPAYJpFaqm33aDhJCVduIqBBVIofeLO-uV0RKd0OcgPLP-CH8IGb2xYVQLj1w3MfIWu_M-Bv7mxnGXos4MF4kYx5lecKjQRbwJEw97gs6cxKR9Yypmk3I8VhdXAzOt9iPNheGaJWtT6wcdVamtEfeHwQIrAOhvH7esCLOT4bv5185NZCig9a2m0atIWd2_R2jN_dudIK_-k0QDE8nxx9402CAp4hyljyKjWcx6PciE2KgkIcmUXkqMikSo_KQwJPCCyPQEIywWeCHMhM2FzZOEo-2QtH535Ah6jDlqB935BJf1uRJP5Iep4Lvv3OH-p-7m3u-vy_pZI57m1bFTai3Wv2Gd_7febvLbjeIG45qE7nHtmxxn-18ajgFD9jPU6qiYdI1mCIDZ3K7XEOZg13MyuW0mCZAzJWVA1TvyyZfbQ3TAhztJWSccDp0fH2SbGrVOqBNbmhZFgdQlAV3l2Y243RcAjP0s5DSs0X95rwsF0CEuaJ0Uwd7k9HkaLz_FgwgoMhKtEibQcUArSi19gCo9xlHO7azA5h_QUACIVQFgx-yyXVM6SO2jR9hnzBIlQ1SP_CNSuIoydUginNr_DSMlIgzqXosalVNp00deGpHMtMd4Y80VJOGYnyoKw3VXo8ddmLzuhDKVQKi1WPdZvniuqRxqb5KUP5J0LrGuzrtaxdor5YmYeqehKIoqTrJBkDWwPBfBt1tzUd343S202Ovuqf4s0lJTGHLlaOS30qFCqOKHoMN7wwCDBsExu099rg24m4GKRNdqlA-_evwL9kOGq3-OBqf7bJbCNmDmgX5jG0vFyv7nN1Mvy2nbvGickLA9DUb7y_aGcIn |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+and+safety+of+erlotinib+versus+chemotherapy+in+second-line+treatment+of+patients+with+advanced%2C+non-small-cell+lung+cancer+with+poor+prognosis+%28TITAN%29%3A+a+randomised+multicentre%2C+open-label%2C+phase+3+study&rft.jtitle=The+lancet+oncology&rft.au=Ciuleanu%2C+Tudor&rft.au=Stelmakh%2C+Lilia&rft.au=Cicenas%2C+Saulius&rft.au=Miliauskas%2C+Skaidrius&rft.date=2012-03-01&rft.issn=1470-2045&rft.volume=13&rft.issue=3&rft.spage=300&rft.epage=308&rft_id=info:doi/10.1016%2FS1470-2045%2811%2970385-0&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1470_2045_11_70385_0 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204512X71353%2Fcov150h.gif |